John MacDonald of Blast Energy Services Inc

Meanwhile, Blast has already begun the capture ofadditional drilling opportunities, including the execution of a recent MasterService Agreement with Resource Energy Technologies in Kentucky where thelateral drilling process may allow producers to significantly increase theirproduction flow rates of natural gas from limestone formations similar to theAustin Chalk. Website address http:// Harbor StatementThis press release contains forward-looking statements within the meaning ofthe Private Securities Litigation Reform Act of 1995 (the "Act"). Inparticular, when used in the preceding discussion, the words "believes,""expects," "intends," "plans," "anticipates," or "may," and similarconditional expressions are intended to identify forward-looking statementswithin the meaning of the Act, and are subject to the safe harbor created bythe Act. Any statements made in this news release other than those ofhistorical fact, about an action, event or development, are forward-lookingstatements. Forward looking statements involve known and unknown risks anduncertainties, which may cause the Company's actual results in future periodsto be materially different from any future performance that may be suggestedin this release.

Such factors may include risk factors including but notlimited to: the likelihood that the customer lawsuits result in meaningfulproceeds, the ability to raise necessary capital to fund growth, adequateliquidity to manage operations and debt obligations, the introduction of newservices, commercial acceptance and viability of new services, fluctuations incustomer demand and commitments, pricing and competition, reliance uponlenders, contractors and vendors, the ability of Blast Energy Services'customers to pay for our services, together with such other risk factors asmay be included in the Company's filings on its periodic filings on Form 10-K,10-Q, and other current reports Blast Energy Services, Inc. takes noobligation to update or correct forward-looking statements, and also takes noobligation to update or correct information prepared by third parties that arenot paid for by Blast.SOURCEBlast Energy Services, Inc.John MacDonald of Blast Energy Services, Inc.,1-281-453-2888, or1-713-725-9244, . (TSX:SBS), abiotechnology company developing protein pharmaceuticals in crop plants, todayannounced it has received US$2,500,000 from MannKind Corporation (Nasdaq:MNKD)as consideration for the option agreement and issuance of 2,400,000 units ofSemBioSys, as previously announced December 24, 2008. The transaction providesMannKind with the option to the license rights to SemBioSys' proprietaryplant-produced recombinant human insulin for use primarily in MannKind'sultra-rapid acting insulin, AFRESA(TM).The units were issued at a price US$0.83(Cdn$1.00) per unit. Each whole warrant entitlesMannKind to purchase one additional common share of SemBioSys at an exerciseprice of Cdn$6.00 for a period of 36 months from the effective date of theoption.

The option period for the license rights ends on March 31, 2009.About SBS Plant-Produced InsulinSemBioSys' plant-produced insulin is human insulin produced from geneticallyenhanced safflower. SemBioSys has demonstrated that its plant-produced insulinis physically, structurally and functionally indistinguishable frompharmaceutical-grade human insulin through analytical testing and pre-clinicalsub-chronic toxicology studies in rodents and primates. SemBioSys is currentlyconducting a Phase I/II clinical trial of its plant-produced insulin. Thethree-arm study, of up to 30 healthy volunteers, is designed to demonstratethe bioequivalence of safflower-produced insulin to two commercial insulinstandards. Full results are expected to be available during the first half of2009.About SemBioSysCalgary, Alberta-based SemBioSys is a biotechnology company developingprotein-based pharmaceuticals using its proprietary protein productiontechnology. SemBioSys' leadpharmaceutical candidates are recombinant human insulin, which is intended toserve the rapidly expanding global diabetes market, and Apo AI(Milano).